Among adv-cSCC patients, those with progressive disease (PD) exhibited higher baseline CFH levels than those achieving clinical benefit (CR, PR, or SD), although this difference did not reach statistical significance (median = 580.6 vs. 319.6 pg/mL; p = 0.0816; Figure 1B). The gene discussed is CFH; the disease is skin squamous cell carcinoma.